Press Releases

Date Title
10/12/21 Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2021
10/12/21 Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
10/11/21 Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne
10/4/21 Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio
10/4/21 Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
9/30/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/27/21 Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA
9/14/21 Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress
9/7/21 Sarepta Therapeutics to Present at Upcoming Investor Conferences
9/7/21 Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
Displaying 71 - 80 of 768